An anti-CD30 chimeric receptor that mediates CD3-ε-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30

Cancer Research

Volumn 58, Issue 6, 1998, Pages 1116-1119

  Hombach, Andreas ^a   Heuser, Claudia ^a   Sircar, Ranjan ^a   Tillmann, Thorsten ^a   Diehl, Volker ^a   Pohl, Christoph ^b   Abken, Hinrich ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Evangelisches Krankenhaus Kalk   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD30 ANTIGEN; CHIMERIC PROTEIN; CYTOKINE ANTIBODY; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY HRS3; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HODGKIN DISEASE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REED STERNBERG CELL; T LYMPHOCYTE ACTIVATION; TUMOR CELL LINE;

ANTIGENS, CD3; ANTIGENS, CD30; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HODGKIN DISEASE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LYMPHOCYTE ACTIVATION; RECOMBINANT FUSION PROTEINS; SOLUBILITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032521416     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Stein, H., Schwarting, R., Dallenbach, F., and Dienmann, D. Immunology of Hodgkin and Reed-Sternberg cells. Recent Results Cancer Res., 117: 14-26, 1989.
2. Oudejahns, J. J., Jiwa, N. M., Kummer, J. A., Horstmann, A., Vos, W., Baak, J. P., Kluin, P. M., Van der Valk, P., Walboomers, J. M., and Meijer, C. J. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood, 87: 3844-3851, 1996.
3. Renner, C., Ohnesorge, S., Held, G., Bauer, S., Jung, W., Pfitzenmeier, J. P., and Pfreundschuh, M. T cells from patients with Hodgkin's disease have a defective T-cell receptor ζ chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood, 88: 236-241, 1996.
4. Abken, H., Hombach, A., Reinhold, U., and Ferrone, S. Can combined T cell-and antibody-based immunotherapy outsmart tumor cells? Immunol. Today, 19: 2-5, 1998.
5. Eshhar, Z., Waks, T., Gross, G., and Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA, 90: 720-724, 1993.
6. Hwu, P., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A., and Eshhar, Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J. Exp. Med., 178: 361-366, 1993.
7. + T cells. J. Immunol., 151: 2380-2389, 1993.
8. Renner, C., and Pfreundschuh, M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol. Rev., 145: 179-209, 1995.
9. Pizzolo, G., Vinant, F., Chilosi, M., Dallenbach, F., Josimovich-Alasevic, O., Diamantenstein, T., and Stein, H. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br. J. Haematol., 75: 282-284, 1990.
10. Gause, A., Pohl, C., Tschiersch, A., Da-Costa, L., Jung, W., Diehl, V., Hasenclever, D., and Pfreundschuh, M. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood, 77: 1983-1988, 1991.
11. Diehl, V., Burrichter, H., Schaadt, M., Kirchner, H., H., Fonatsch, C., Stein, H., Gerdes, J., Heit, W., and Ziegler, A. Hodgkin's disease cell lines: characteristics and biological activities. Hamatol. Bluttransfus., 28: 411-417, 1983.
12. Lenoir, G. M., Philip, T., and Sohier, R. Burkitt type lymphoma-EBV association and cytogenetic markers in cases from various geographic locations. In: I. T. Magrath, G. T. O'Conor, and B. Ramot (eds.), Pathogenesis of Leukemias and Lymphomas: Environmental Influences, p. 283. New York: Raven Press, 1994.
13. Engert, A., Martin, G., Pfreundschuh, H. M., Amlot, P., Hsu, S. M., Diehl, V., and Thorpe, P. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab′ fragments on solid human Hodgkin's disease tumors in mice. Cancer Res., 90: 2929-2935, 1990.
14. Pohl, C., Renner, C., Schwonzen, M., Schobert, I., Liebenberg, V., Jung, W., Wolf, J., Pfreundschuh, M., and Diehl, V. CD30 specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma. Int. J. Cancer, 54: 418-425, 1993.
15. Renner, C., Jung, W., Sahin, U., Van-Lier, R., and Pfreundschuh, M. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur. J. Immunol., 25: 2027-2033, 1995.
16. Küster, H., Thompson, H., and Kinet, J. P. Characterization and expression of the gene for the human Fc receptor γ subunit. J. Biol. Chem., 265: 6448-6452, 1990.
17. Orloff, D. G., Ra, C., Frank, S. J., Klausner, R. D., and Kinel, J. P. Family of disulfide-linked dimers containing the ζ and η chains of the T-cell receptor and the γ chain of Fc receptors. Nature (Lond.), 347: 189-191, 1990.
18. + tumor cells. Gastroenterology, 113: 1163-1170, 1997.
19. Blomberg, K., and Ulfstedt, A. C. Fluorescent europium chelates as target cell markers in the assessment of natural killer cell cytotoxicity. J. Immunol. Methods, 160: 27-34, 1993.
20. Josimovich-Alasevic, O., Dürkop, H., Schwarting, R., Backé, E., Stein, H., and Diamantenstein, T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. partial characterization of the soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur. J. Immunol., 19: 157-162, 1989.